 |
4 Products |  |
191 Diseases | | 4 Products |
|
9 Trials |  |
341 News |  |
| «123» |
- | CLD-101 / Calidi Biotherap
Enrollment closed, Trial completion date, Oncolytic virus: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Oct 13, 2020
P1, N=13, Active, not recruiting, Sponsor: Northwestern University
Completed --> Active, not recruiting | Trial completion date: Apr 2020 --> Dec 2021
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] Clinical results after autologous hematopoietic stem cell transplantation with betibeglogene autotemcel (beti-cel, LentiGlobin for ß-thalassemia) gene therapy in phase 3 Nothstar-2 and Northstar-3 studies in transfusion-dependent ß-thalassemia (TDT) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_2074;
P3
89% and 75% of evaluable patients in Northstar-2 and -3 achieved TI. Safety is consistent with that of single-agent busulfan myeloablation.
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] Clinical results after autologous hematopoietic stem cell transplantation with betibeglogene autotemcel (beti-cel, LentiGlobin for ß-thalassemia) gene therapy in phase 3 Nothstar-2 and Northstar-3 studies in transfusion-dependent ß-thalassemia (TDT) (San Francisco) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1938;
P3
89% and 75% of evaluable patients in Northstar-2 and -3 achieved TI. Safety is consistent with that of single-agent busulfan myeloablation.
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] Clinical results after autologous hematopoietic stem cell transplantation with betibeglogene autotemcel (beti-cel, LentiGlobin for ß-thalassemia) gene therapy in phase 3 Nothstar-2 and Northstar-3 studies in transfusion-dependent ß-thalassemia (TDT) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_1370;
P3
89% and 75% of evaluable patients in Northstar-2 and -3 achieved TI. Safety is consistent with that of single-agent busulfan myeloablation.
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] Clinical results after autologous hematopoietic stem cell transplantation with betibeglogene autotemcel (beti-cel, LentiGlobin for ß-thalassemia) gene therapy in phase 3 Nothstar-2 and Northstar-3 studies in transfusion-dependent ß-thalassemia (TDT) (Abstract video presentations) - Sep 3, 2020 - Abstract #DGHO2020DGHO_611;
P3
89% and 75% of evaluable patients in Northstar-2 and -3 achieved TI. Safety is consistent with that of single-agent busulfan myeloablation.
- | NU-0129 / Northwestern University, Exicure
Trial completion date, Surgery: NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery (clinicaltrials.gov) - Aug 19, 2020
P1, N=8, Active, not recruiting, Sponsor: Northwestern University
Safety is consistent with that of single-agent busulfan myeloablation. Trial completion date: Jul 2022 --> Sep 2020
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: CAST: Cardiac Safe Transplants for Systemic Sclerosis (clinicaltrials.gov) - Aug 12, 2020
P2/3, N=9, Terminated, Sponsor: Northwestern University
Trial completion date: Jul 2022 --> Sep 2020 N=50 --> 9 | Trial completion date: Jan 2026 --> Oct 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Oct 2019; PI Sabbatical
- | Triapine (3-AP) / Vion, Northwestern University
New P1 trial: Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy (clinicaltrials.gov) - Aug 6, 2020
P1, N=12, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | autologous hematopoietic stem cell therapy / Northwestern University
Trial completion, Trial completion date: Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov) - Jul 23, 2020
P2, N=80, Completed, Sponsor: Northwestern University
N=50 --> 9 | Trial completion date: Jan 2026 --> Oct 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Jan 2025 --> Oct 2019; PI Sabbatical Active, not recruiting --> Completed | Trial completion date: Jul 2020 --> Nov 2019
- Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5256;
However, relapse is high without the addition of rituximab. When rituximab is included 92% improve in mRSS and FVC and maintain remission for > 1 year on no immune based therapies.
- Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5255;
However, relapse is high without the addition of rituximab. When rituximab is included 92% improve in mRSS and FVC and maintain remission for > 1 year on no immune based therapies.
- Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_5254;
However, relapse is high without the addition of rituximab. When rituximab is included 92% improve in mRSS and FVC and maintain remission for > 1 year on no immune based therapies.
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4986;
P3
In Northstar-2, 90% of patients achieved the primary endpoint of TI. The safety profile is consistent with single-agent busulfan myeloablation.
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4985;
P3
In Northstar-2, 90% of patients achieved the primary endpoint of TI. The safety profile is consistent with single-agent busulfan myeloablation.
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_4984;
P3
In Northstar-2, 90% of patients achieved the primary endpoint of TI. The safety profile is consistent with single-agent busulfan myeloablation.
- [VIRTUAL] A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2708;
Alternatively, the infused donor graft may have provided a non-CD3+, non-CD33+ non-hematopoietic type of stem cell such as donor mesenchymal stem cells that in theory could facilitate a durable remission. Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053
- [VIRTUAL] A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2707;
Alternatively, the infused donor graft may have provided a non-CD3+, non-CD33+ non-hematopoietic type of stem cell such as donor mesenchymal stem cells that in theory could facilitate a durable remission. Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053
- [VIRTUAL] A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE (ePoster Area) - Jul 3, 2020 - Abstract #EBMT2020EBMT_2706;
Alternatively, the infused donor graft may have provided a non-CD3+, non-CD33+ non-hematopoietic type of stem cell such as donor mesenchymal stem cells that in theory could facilitate a durable remission. Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053
- | CLD-101 / Calidi Biotherap
Trial completion, Enrollment change, Oncolytic virus: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Apr 8, 2020
P1, N=13, Completed, Sponsor: Northwestern University
Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053 Recruiting --> Completed | N=36 --> 13
- | SB-001 / Solid BioSciences
Journal: Phenotype-based discovery of a HeLa-specific cytotoxic molecule that downregulates HPV-mediated signaling pathways via oxidative damage. (Pubmed Central) - Feb 28, 2020
The subsequent mechanistic study revealed that SB2001 induced apoptotic cell death through restoring p53 function and suppressed the human papillomavirus (HPV)-mediated oncoprotein signaling pathway via oxidative damage in HeLa cells. SB2001 also selectively induced HeLa-specific tumor regression without any adverse effects in an in vivo tumor xenograft model, demonstrating its potential as a promising chemical probe.
- Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] CARDIAC SAFE HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS WITH COMPROMISED CARDIAC FUNCTION (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_2102;
However, relapse is high without the addition of rituximab. When rituximab is included 92% improve in mRSS and FVC and maintain remission for > 1 year on no immune based therapies.
- autologous hematopoietic stem cell therapy / Northwestern University
[VIRTUAL] CLINICAL OUTCOMES FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH LENTIGLOBIN GENE THERAPY IN THE PHASE 3 NORTHSTAR-2 AND NORTHSTAR-3 STUDIES FOR TRANSFUSION-DEPENDENT β-THALASSEMIA (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_1997;
P3
In Northstar-2, 90% of patients achieved the primary endpoint of TI. The safety profile is consistent with single-agent busulfan myeloablation.
- [VIRTUAL] A PILOT FEASIBILITY STUDY OF NON-MYELOABLATIVE ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR REFRACTORY CROHN DISEASE (ePoster Area) - Feb 8, 2020 - Abstract #EBMT2020EBMT_927;
Alternatively, the infused donor graft may have provided a non-CD3+, non-CD33+ non-hematopoietic type of stem cell such as donor mesenchymal stem cells that in theory could facilitate a durable remission. Clinical Trial Registry: FDA IND 16908, www.clinicaltrials.gov NCT 01288053
- | SB-001 / Solid BioSciences, SB-002 / Solid BioSciences
Journal: Variability in the immunogenic preS region of Pakistani hepatitis B virus isolates. (Pubmed Central) - Dec 8, 2019
Sequencing results showed that eight samples (SBS002-SBS008) have a deletion of 33 nucleotides at N-terminal that is characteristics of genotype D while SBS001 belongs to genotype C. Silent mutations and amino acid changes were also searched in this highly variable region of genome. Based upon this study it was concluded that genotype D is the most common genotype in Pakistan.
- | autologous hematopoietic stem cell therapy / Northwestern University
Trial completion date, Trial primary completion date: Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov) - Nov 10, 2019
P2, N=80, Active, not recruiting, Sponsor: Northwestern University
Based upon this study it was concluded that genotype D is the most common genotype in Pakistan. Trial completion date: Jan 2020 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2019
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
Enrollment change, Trial withdrawal: ATTEND: Autologous Transplant To End NMO Spectrum Disorder (clinicaltrials.gov) - Nov 8, 2019
P2/3, N=0, Withdrawn, Sponsor: Northwestern University
Trial completion date: Jan 2020 --> Jul 2020 | Trial primary completion date: Dec 2018 --> Jul 2019 N=50 --> 0 | Recruiting --> Withdrawn
- Keytruda (pembrolizumab) / Merck (MSD), Neupogen (filgrastim) / Kyowa Hakko Kirin, Roche, Amgen, Opdivo (nivolumab) / Ono Pharma, BMS
Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_5763;
P2
We found no significant hindrance to peripheral blood stem cell harvest and PEM- related AEs were uncommon. Additionally, pre-treatment with a checkpoint inhibitor prior to autoHSCT appears safe thus far and does not appear to delay engraftment.
- | CLD-101 / Calidi Biotherap
Trial completion date, Trial primary completion date, Oncolytic virus: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Aug 28, 2019
P1, N=36, Recruiting, Sponsor: Northwestern University
Additionally, pre-treatment with a checkpoint inhibitor prior to autoHSCT appears safe thus far and does not appear to delay engraftment. Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
Trial initiation date: ATTEND: Autologous Transplant To End NMO Spectrum Disorder (clinicaltrials.gov) - Jul 25, 2019
P2/3, N=50, Recruiting, Sponsor: Northwestern University
Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Mar 2019 --> Mar 2020 Initiation date: Jun 2019 --> Nov 2019
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
Enrollment closed: CAST: Cardiac Safe Transplants for Systemic Sclerosis (clinicaltrials.gov) - Jul 25, 2019
P2/3, N=50, Active, not recruiting, Sponsor: Northwestern University
Initiation date: Jun 2019 --> Nov 2019 Recruiting --> Active, not recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
Trial initiation date: ATTEND: Autologous Transplant To End NMO Spectrum Disorder (clinicaltrials.gov) - May 2, 2019
P2/3, N=50, Recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting Initiation date: Mar 2019 --> Jun 2019
- | autologous hematopoietic stem cell therapy / Northwestern University
Trial completion date, Trial primary completion date: Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov) - Apr 20, 2019
P2, N=80, Active, not recruiting, Sponsor: Northwestern University
Initiation date: Mar 2019 --> Jun 2019 Trial completion date: Dec 2018 --> Jan 2020 | Trial primary completion date: Feb 2018 --> Dec 2018
- | SB-001 / Solid BioSciences
Journal: Label-free target identification reveals oxidative DNA damage as the mechanism of a selective cytotoxic agent. (Pubmed Central) - Apr 19, 2019
MTH1 was identified by both TS-FITGE and TPP, and SB2001 inhibited the function of MTH1 in hydrolyzing oxidized nucleotides. Compared to CaSki cells, HeLa cells displayed downregulated DNA mismatch repair pathways, which made HeLa cells more susceptible to the oxidative stress caused by SB2001, resulting in increased 8-oxoG concentrations, DNA damage, and subsequent cell death.
- | Triapine (3-AP) / Vion, Northwestern University
Phase classification, Enrollment change, Trial primary completion date, Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Apr 9, 2019
P3, N=348, Recruiting, Sponsor: National Cancer Institute (NCI)
Compared to CaSki cells, HeLa cells displayed downregulated DNA mismatch repair pathways, which made HeLa cells more susceptible to the oxidative stress caused by SB2001, resulting in increased 8-oxoG concentrations, DNA damage, and subsequent cell death. Phase classification: P2 --> P3 | N=188 --> 348 | Trial primary completion date: Sep 2018 --> Jul 2023
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
New P2/3 trial: ATTEND: Autologous Transplant To End NMO Spectrum Disorder (clinicaltrials.gov) - Feb 4, 2019
P2/3, N=50, Recruiting, Sponsor: Northwestern University
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment closed, Enrollment change: Stem Cell Transplantation for Stiff Person Syndrome (SPS) (clinicaltrials.gov) - Jan 31, 2019
P1/2, N=23, Active, not recruiting, Sponsor: Northwestern University
Phase classification: P2 --> P3 | N=188 --> 348 | Trial primary completion date: Sep 2018 --> Jul 2023 Recruiting --> Active, not recruiting | N=40 --> 23
- | NU-0129 / Northwestern University, Exicure
Enrollment closed, Surgery: NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery (clinicaltrials.gov) - Aug 22, 2018
P1, N=8, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Active, not recruiting | N=40 --> 23 Recruiting --> Active, not recruiting
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi, autologous hematopoietic stem cell therapy / Northwestern University
New P2/3 trial: CAST: Cardiac Safe Transplants for Systemic Sclerosis (clinicaltrials.gov) - Jul 20, 2018
P2/3, N=50, Recruiting, Sponsor: Northwestern University
- | Triapine (3-AP) / Vion, Northwestern University
Trial initiation date, Trial suspension, Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Jan 8, 2018
P2, N=188, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Aug 2017 --> Jan 2016 | Recruiting --> Suspended
- | Triapine (3-AP) / Vion, Northwestern University
Trial initiation date, Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - Sep 8, 2017
P2, N=188, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Aug 2017 --> Jan 2016 | Recruiting --> Suspended Initiation date: Jan 2016 --> Aug 2017
- | Triapine (3-AP) / Vion, Northwestern University
Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - May 19, 2017
P2, N=188, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Jan 2016 --> Aug 2017 Suspended --> Recruiting
- | NU-0129 / Northwestern University, Exicure
Enrollment open, Trial initiation date, Surgery: NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery (clinicaltrials.gov) - May 18, 2017
P, N=8, Recruiting, Sponsor: Northwestern University
Suspended --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017
- | Triapine (3-AP) / Vion, Northwestern University
Combination therapy, Metastases: NRG-GY006: Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers (clinicaltrials.gov) - May 17, 2017
P2, N=188, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 Recruiting --> Suspended
- | CLD-101 / Calidi Biotherap
Enrollment open, Oncolytic virus: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Apr 25, 2017
P1, N=36, Recruiting, Sponsor: Northwestern University
Recruiting --> Suspended Not yet recruiting --> Recruiting
- | CLD-101 / Calidi Biotherap
New P1 trial, Oncolytic virus: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (clinicaltrials.gov) - Mar 7, 2017
P1, N=36, Not yet recruiting, Sponsor: Northwestern University
- | autologous hematopoietic stem cell therapy / Northwestern University
Trial completion: Safety and Efficacy Study of Autologous Stem Cell Transplantation for Early Onset Type I Diabetes Mellitus (clinicaltrials.gov) - Jan 18, 2017
P1/2, N=25, Completed, Sponsor: University of Sao Paulo
Not yet recruiting --> Recruiting Recruiting --> Completed
- NU-0129 / Northwestern University, Exicure
New trial, Surgery: NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery (clinicaltrials.gov) - Jan 13, 2017
P0, N=8, Not yet recruiting, Sponsor: Northwestern University
- autologous hematopoietic stem cell therapy / Northwestern University
Enrollment closed: Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov) - Sep 19, 2016
P2, N=80, Active, not recruiting, Sponsor: Northwestern University
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment change, Trial termination, Trial primary completion date: Hematopoietic Stem Cell Support in Vasculitis (clinicaltrials.gov) - Jul 13, 2016
P1, N=7, Terminated, Sponsor: Northwestern University
N=10 --> 7 | Recruiting --> Terminated | Trial primary completion date: Aug 2017 --> Jun 2016; No participant enrolled over five years. No plan to continue the study.
- autologous hematopoietic stem cell therapy / Northwestern University
Trial primary completion date: Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy (clinicaltrials.gov) - Mar 22, 2016
P2, N=80, Recruiting, Sponsor: Northwestern University
No plan to continue the study. Trial primary completion date: Dec 2016 --> Dec 2017